Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 20/20 | 0.66 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.61 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.61 |
| ▸ | NQO2 | P16083 | 1/20 | 0.61 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.61 |
| ▸ | PDE1A | P54750 | 1/20 | 0.53 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.53 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.53 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.53 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9910500 | 0.91 | MET (0.79) | METPDE3BPDE3ANQO2PIP4K2C | |
| SCHEMBL10242471 | 0.90 | MET (0.71) | METPDE3BPDE3ANQO2PIP4K2C | |
| SCHEMBL12049397 | 0.88 | MET (0.68) | METPDE3BPDE3ANQO2PIP4K2C | |
| SCHEMBL10242512 | 0.87 | MET (0.73) | METPDE3BPDE3ANQO2PIP4K2C | |
| SCHEMBL10242511 | 0.85 | MET (0.65) | METPDE3BPDE3ANQO2PIP4K2C | |
| SCHEMBL14199066 | 0.85 | MET (0.67) | METPDE3BPDE3ANQO2PIP4K2C | |
| SCHEMBL12049424 | 0.84 | MET (0.57) | METPDE3BPDE3ANQO2PIP4K2C | |
| SCHEMBL12049398 | 0.83 | MET (0.64) | METPDE3BPDE3ANQO2PIP4K2C | |
| SCHEMBL10242462 | 0.82 | MET (0.59) | METPDE3BPDE3ANQO2PIP4K2C | |
| SCHEMBL9910501 | 0.81 | MET (0.86) | METPDE3BPDE3ANQO2PIP4K2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120107275-A1 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120107275-A1 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | HGF, HGFAC, MET | MET 3/4885PDE3B 1730/4885PDE3A 1765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.